COM:RELMADA
Relmada Therapeutics, Inc.
- Stock
Last Close
2.85
21/11 21:00
Market Cap
128.54M
Beta: -
Volume Today
250.57K
Avg: -
Preview
Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page
Jun '14 | Jun '15 | Jun '16 | Jun '17 | Jun '18 | Jun '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
average inventory | 1.58K - | 267.40K - | 478.25K 78.85% | 424.30K 11.28% | 473.85K 11.68% | 712K 50.26% | 6.10M 757.07% | 7.67M 25.66% | 2.02M 73.69% | ||
average payables | 389.88K - | 790.69K 102.80% | 1.05M 32.48% | 894.63K 14.59% | 647.50K 27.62% | 844.90K 30.49% | 4.64M 448.64% | 9.77M 110.76% | 8.23M 15.79% | 4.38M 46.71% | |
average receivables | 115.95K - | 287.31K 147.79% | 207.41K 27.81% | 159.59K 23.05% | 163.27K 2.30% | 82.92K 49.21% | 299.40K 261.09% | 256.22K 14.42% | |||
book value per share | 3.54 - | 2.43 31.49% | 0.48 80.08% | -1.76 463.36% | 1.21 168.62% | 6.77 461.31% | 11.87 75.24% | 4.74 60.05% | 2.84 40.17% | ||
capex per share | -0.01 - | -0.19 1,965.91% | -0.02 91.51% | -0.00 76.00% | |||||||
capex to depreciation | -2.52 - | -10.26 306.99% | -0.58 94.32% | -4.72 709.43% | |||||||
capex to operating cash flow | 0.00 - | 0.04 2,875.81% | 0.01 82.04% | 0.00 73.13% | |||||||
capex to revenue | |||||||||||
cash per share | 9.04 - | 2.93 67.58% | 0.57 80.67% | 0.71 25.98% | 1.46 104.55% | 7.51 414.21% | 12.07 60.79% | 5.01 58.53% | 3.20 36.07% | ||
days of inventory on hand | |||||||||||
days payables outstanding | |||||||||||
days sales outstanding | |||||||||||
debt to assets | 0.01 - | 0.03 147.07% | 0.10 265.05% | 0.97 889.57% | 0.04 96.31% | ||||||
debt to equity | 0.03 - | 0.04 29.80% | 0.19 387.55% | -0.53 381.62% | 0.05 108.97% | ||||||
dividend yield | |||||||||||
earnings yield | -0.21 - | -0.11 45.44% | -0.63 464.48% | -0.71 11.38% | -0.38 46.71% | -0.12 69.19% | -0.32 173.95% | -1.48 364.65% | -0.79 46.36% | ||
enterprise value | -25.56M - | 78.70M 407.84% | 18.22M 76.85% | 8.47M 53.53% | 13.37M 57.95% | 37.10M 177.39% | 497.61M 1,241.37% | 351.02M 29.46% | 98.01M 72.08% | 120.52M 22.97% | |
enterprise value over ebitda | -4.61 - | -0.62 86.49% | -1.08 73.28% | -2.15 99.80% | -4.17 93.56% | -8.18 96.15% | -2.82 65.53% | -0.63 77.79% | -1.16 85.51% | ||
ev to operating cash flow | -4.85 - | -1.39 71.42% | -1.31 5.54% | -2.23 70.16% | -3.53 58.60% | -17.89 406.37% | -3.82 78.65% | -0.94 75.29% | -2.33 147.09% | ||
ev to sales | |||||||||||
free cash flow per share | -6.54 - | -4.73 27.71% | -2.16 54.33% | -1.92 11.16% | -1.66 13.27% | -1.78 7.22% | -5.23 193.51% | -3.50 33.07% | -1.72 51.01% | ||
free cash flow yield | -0.16 - | -0.52 221.81% | -0.66 26.98% | -0.47 27.88% | -0.23 51.87% | -0.06 75.66% | -0.23 317.80% | -1.00 332.10% | -0.41 58.70% | ||
graham net net | 2.77 - | 1.98 28.57% | 0.27 86.58% | -1.93 826.82% | 1.12 157.91% | 6.73 502.31% | 11.54 71.39% | 4.67 59.57% | 2.80 40.10% | ||
graham number | 25.84 - | 7.49 71.02% | 4.76 36.41% | 10.63 123.27% | 8.63 18.82% | 23.82 176.01% | 43.74 83.65% | 23.45 46.38% | 14.47 38.30% | ||
income quality | 0.78 - | 4.42 466.48% | 1.03 76.72% | 0.67 34.88% | 0.61 9.50% | 0.47 22.84% | 0.73 56.20% | 0.66 9.53% | 0.52 20.89% | ||
intangibles to total assets | 0 - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
interest coverage | -3.47K - | -5.17 - | 38.34 - | ||||||||
interest debt per share | 0.11 - | 0.09 12.70% | 0.09 2.88% | 1.36 1,388.34% | 0.06 95.77% | -0.14 - | |||||
inventory turnover | |||||||||||
invested capital | 0.03 - | 0.04 29.80% | 0.19 387.55% | -0.53 381.62% | 0.05 108.97% | ||||||
market cap | 100.90M - | 26.45M 73.79% | 9.90M 62.56% | 12.67M 27.98% | 45.95M 262.64% | 500.11M 988.38% | 395.46M 20.92% | 103.40M 73.85% | 124.61M 20.51% | ||
net current asset value | -1.13M - | 8.39M 841.46% | 6.10M 27.29% | 1.10M 81.99% | -5.82M 630.21% | 7.38M 226.70% | 105.47M 1,329.53% | 208.24M 97.44% | 140.40M 32.58% | 85.31M 39.24% | |
net debt to ebitda | 1.30 - | 0.28 78.38% | 0.18 35.01% | -0.11 161.99% | 1.00 979.05% | 0.04 95.88% | 0.36 770.38% | 0.03 90.34% | 0.04 14.39% | ||
net income per share | -8.37 - | -1.03 87.74% | -2.08 103.01% | -2.86 37.19% | -2.74 3.97% | -3.72 35.72% | -7.17 92.46% | -5.16 28.02% | -3.28 36.37% | ||
operating cash flow per share | -6.53 - | -4.53 30.58% | -2.14 52.74% | -1.91 10.67% | -1.66 13.09% | -1.78 7.22% | -5.23 193.51% | -3.50 33.07% | -1.72 51.01% | ||
payables turnover | |||||||||||
receivables turnover | |||||||||||
research and ddevelopement to revenue | |||||||||||
return on tangible assets | -0.85 - | -0.29 65.95% | -2.22 663.12% | -2.94 32.67% | -1.69 42.36% | -0.49 71.00% | -0.56 14.64% | -1.00 77.45% | -1.01 1.31% | ||
revenue per share | |||||||||||
roe | -2.36 - | -0.42 82.11% | -4.30 919.18% | 1.63 137.76% | -2.27 239.95% | -0.55 75.82% | -0.60 9.82% | -1.09 80.17% | -1.16 6.35% | ||
roic | -1.88 - | 7.55 500.67% | -3.68 148.76% | 2.88 178.19% | -1.24 143.16% | -0.56 54.71% | -0.60 7.29% | -1.12 85.07% | -1.21 8.72% | ||
sales general and administrative to revenue | |||||||||||
shareholders equity per share | 3.54 - | 2.43 31.49% | 0.48 80.08% | -1.76 463.36% | 1.21 168.62% | 6.77 461.31% | 11.87 75.24% | 4.74 60.05% | 2.84 40.17% | ||
stock based compensation to revenue | |||||||||||
tangible asset value | -1.11M - | 8.81M 894.43% | 7.04M 20.06% | 1.46M 79.26% | -5.51M 477.53% | 7.61M 238.10% | 105.58M 1,286.82% | 208.26M 97.25% | 140.44M 32.57% | 85.36M 39.22% | |
tangible book value per share | 3.54 - | 2.43 31.49% | 0.48 80.08% | -1.76 463.36% | 1.21 168.62% | 6.77 461.31% | 11.87 75.24% | 4.74 60.05% | 2.84 40.17% | ||
working capital | -1.03M - | 8.39M 913.38% | 6.24M 25.61% | 1.10M 82.39% | -3.17M 388.34% | 7.38M 332.98% | 105.47M 1,329.53% | 208.24M 97.44% | 140.40M 32.58% | 85.31M 39.24% |
All numbers in (except ratios and percentages)